Neuroendocrine Tumor

PRNETs, though rare, should be considered in the differential diagnosis of renal masses, particularly in patients with congenital renal abnormalities such as horseshoe kidney. Nephron-sparing surgery may be a feasible option in selected cases, with favorable short-term outcomes. Long-term follow-up is essential due to the potential for delayed metastasis. Immunohistochemical profiling plays a critical role in diagnosis and therapeutic planning, especially regarding the potential use of somatostatin analogs.

Surgery proved a mature teratoma harboring an ACTH-secreting NET (G1). This rare case demonstrates that in pediatric patients with aggressive-appearing presacral masses and life-threatening hypercortisolism, complementary imaging modalities may be necessary to exclude malignancy while identifying the functional tumor source.

Notably, we identify ANGPT2, PCSK1N, and GPX3 as key subtype-specific biomarkers, with ANGPT2 driving tumor progression in C1 and emerging as a potential therapeutic target. Our findings provide a refined molecular classification integrating immune and genomic features in human PPGLs, offering a framework for improved prognostication and precision therapies in this rare neuroendocrine tumor type.

Long-term cardiac prognosis is determined by right ventricular function and presence of residual tumor after resection. Management requires individualized and multidisciplinary surgical planning, balancing tumor resection with timely cardiac intervention.

One year after these treatments started, everolimus (mTOR inhibitor) 10 mg p.o. was administered every day...Although recurrent diseases were temporally controlled by these multidisciplinary treatments for the last month, he died of multiple metastases six years later, after tumor recurrence was detected. This case underscores the potential for late recurrence even in rectal NET G1 with unfavorable histological features, highlighting the importance of long-term surveillance.

This study reveals a new functional role of APOE that leads to chemoresistance in patient treatment. Our findings suggest the potential of combined administration of BLT-1 to overcome TMZ chemoresistance and improve treatments for patients with pNETs.

Acid suppressant-associated gNETs have an indolent course, are often multiple, and are frequently associated with very prolonged PPI/H2RA use. Unconventional morphologies like those described in type 1 gNETs may be observed.

This study suggests that DOCK10 may serve as a diagnostic marker for insulin-secreting lesions and a potential therapeutic target in insulinoma. It provides mechanistic insights that may inform future strategies for precision diagnostics and treatment of functional pancreatic neuroendocrine tumors.

This validation study demonstrates statistically significant improvements in PancreaSeq GC for mucinous cysts and advanced neoplasia, establishing it as a clinically valuable tool for the preoperative evaluation of pancreatic cysts.

P2, N=35, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

P1, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026